Amended Statement of Ownership (sc 13g/a)
February 01 2021 - 4:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G/A
Under the Securities Exchange Act of
1934
(Amendment No. 1)*
SORRENTO
THERAPEUTICS, INC.
(Name of Issuer)
Common
Stock, $0.0001 par value
(Title of Class of Securities)
83587F202
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 83587F202
1
|
Name of Reporting Person
Hongguo International Holdings Limited
|
2
|
Check the Appropriate
Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
|
3
|
SEC Use Only
|
4
|
Citizenship or Place
of Organization
British Virgin Islands
|
number
of shares beneficially owned by each reporting person with
|
5
|
Sole Voting
Power
4,074,000(1)
|
6
|
Shared
Voting Power
0
|
7
|
Sole
Dispositive Power
4,074,000
(1)
|
8
|
Shared
Dispositive Power
0
|
9
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
4,074,000
(1)
|
10
|
Check if the
Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11
|
Percent
of Class Represented by Amount in Row (9)
1.5%(2)
|
12
|
Type of
Reporting Person (See Instructions)
CO
|
(1)
Comprised of 4,074,000 shares of the Issuer’s common stock (“Common Stock”) held directly by Hongguo International
Holdings Limited (the “Reporting Person”).
(2)
Percentage based on 262,938,148 shares of Common Stock outstanding as of October 23, 2020, as reported in the Issuer’s
Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020.
Item 1.
(a) Name
of Issuer
Sorrento Therapeutics, Inc.
(b) Address
of Issuer’s Principal Executive Offices
4955 Directors Place
San Diego, CA 92121
Item 2.
(a) Name
of Person Filing
Hongguo International Holdings Limited (the “Reporting
Person”)
(b) Address
of Principal Business office or, if None, Residence
Room 2904, 29th Floor, East Finance Centre
16 Harcourt Road, Admiralty, Hong Kong
(c) Citizenship
British Virgin Islands
(d) Title
of Class of Securities
Common Stock, $0.0001 par value
(“Common Stock”)
(e) CUSIP
Number
83587F202
|
Item 3.
|
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is
a:
|
|
(a)
|
¨
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
|
(b)
|
¨
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
|
(c)
|
¨
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
|
(d)
|
¨
|
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C
80a-8);
|
|
(e)
|
¨
|
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
|
(f)
|
¨
|
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
|
(g)
|
¨
|
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
|
(h)
|
¨
|
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813);
|
|
(i)
|
¨
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
(j)
|
¨
|
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
|
|
(k)
|
¨
|
Group,
in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: __________
|
(a) Amount
beneficially owned:
4,074,000*
(b) Percent
of class:
1.5%**
(c) Number
of shares as to which the person has:
|
(i)
|
Sole power to vote or to direct the vote:
|
4,074,000*
|
(ii)
|
Shared power to vote or to direct the vote:
|
0
|
(iii)
|
Sole power to dispose or to direct the disposition of:
|
4,074,000*
|
(iv)
|
Shared power to dispose or to direct the disposition of:
|
0
|
*
|
Comprised of 4,074,000 shares of Common Stock held directly by the Reporting Person.
|
|
**
|
Percentage based on 262,938,148 shares of Common Stock outstanding as of October 23, 2020, as reported in the Issuer’s
Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020.
|
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than 5 percent of the class of securities, check the following x
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
N/A
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding
Company or Control Person.
|
N/A
|
Item 8.
|
Identification and Classification of Members of the Group.
|
N/A
|
Item 9.
|
Notice of Dissolution of Group.
|
N/A
By signing
below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities
solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 1, 2021
|
Hongguo International Holdings Limited
|
|
|
|
|
|
By:
|
/s/ Yixi Chen
|
|
|
Name: Yixi Chen
|
|
|
Title: Director
|
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024